In addition to Akt, our study further demonstrated that API also suppressed the expression of p-EGFR in EGFR mutant cells (Additional file 1: Figure S4), suggesting the combination of API and EGFR TKI for the treatment of TKI-resistant NSCLC cells is worthy of further investigation. Here, EGFR is linked to non-small cell lung carcinoma.